Balance Sheet
Accounts PayablesAssetsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLoans - NetMinority InterestNon-Current AssetsOther Non-Current AssetsPayablesPrepaid AssetsRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Creative Medical Technology Holdings (CELZ) Cash & Equivalents (2017 - 2025)

Creative Medical Technology Holdings (CELZ) has disclosed Cash & Equivalents for 16 consecutive years, with $5.4 million as the latest value for Q3 2025.

  • On a quarterly basis, Cash & Equivalents fell 14.14% to $5.4 million in Q3 2025 year-over-year; TTM through Sep 2025 was $5.4 million, a 14.14% decrease, with the full-year FY2024 number at $5.9 million, up 71.35% from a year prior.
  • Cash & Equivalents was $5.4 million for Q3 2025 at Creative Medical Technology Holdings, down from $6.5 million in the prior quarter.
  • In the past five years, Cash & Equivalents ranged from a high of $22.9 million in Q2 2022 to a low of $158588.0 in Q2 2021.
  • A 5-year average of $7.4 million and a median of $6.5 million in 2025 define the central range for Cash & Equivalents.
  • Peak YoY movement for Cash & Equivalents: skyrocketed 14317.02% in 2022, then crashed 82.55% in 2023.
  • Creative Medical Technology Holdings' Cash & Equivalents stood at $10.7 million in 2021, then fell by 22.41% to $8.3 million in 2022, then plummeted by 58.33% to $3.5 million in 2023, then skyrocketed by 71.35% to $5.9 million in 2024, then fell by 9.51% to $5.4 million in 2025.
  • Per Business Quant, the three most recent readings for CELZ's Cash & Equivalents are $5.4 million (Q3 2025), $6.5 million (Q2 2025), and $7.7 million (Q1 2025).